IRIDEX (IRIX) Stock Price, News & Analysis

Company Overview

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Key Stats

• Today's Range: $1.15 to $1.17
• 50-Day Range: $0.79 to $1.30
• 52-Week Range: $0.78 to $3.25
• Volume: 19,054 shs
• Average Volume: 45,783 shs
• Market Capitalization: $19.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

IRIDEX Stock Analysis - MarketRank™

IRIDEX scored higher than 45% of companies evaluated by MarketBeat, and ranked 454th out of 658 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

IRIDEX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

IRIDEX has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IRIDEX is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IRIDEX is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IRIDEX has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.22% of the float of IRIDEX has been sold short.

Short Interest Ratio / Days to Cover

IRIDEX has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IRIDEX has recently decreased by 3.85%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IRIDEX does not currently pay a dividend.

Dividend Growth

IRIDEX does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.22% of the float of IRIDEX has been sold short.

Short Interest Ratio / Days to Cover

IRIDEX has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IRIDEX has recently decreased by 3.85%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.98

News Sentiment

IRIDEX has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for IRIDEX this week, compared to 1 article on an average week.

Search Interest

2 people have searched for IRIX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, IRIDEX insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,491.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 7.30% of the stock of IRIDEX is held by insiders.

Percentage Held by Institutions

Only 20.10% of the stock of IRIDEX is held by institutions.

IRIX Stock Analysis - Frequently Asked Questions

How have IRIX shares performed this year?

IRIDEX's stock was trading at $1.68 at the start of the year. Since then, IRIX stock has decreased by 31.3% and is now trading at $1.1550.
View the best growth stocks for 2025 here.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) posted its earnings results on Thursday, March, 27th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The medical equipment provider had revenue of $12.70 million for the quarter, compared to analysts' expectations of $12.80 million. IRIDEX had a negative trailing twelve-month return on equity of 192.95% and a negative net margin of 22.79%.
Read the conference call transcript.

Who are IRIDEX's major shareholders?

Top institutional shareholders of IRIDEX include AMH Equity Ltd (3.09%). Insiders that own company stock include Patrick Mercer, Beverly A Huss, Nandini Devi and Romeo R Dizon.
View institutional ownership trends.

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IRIDEX investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 5/11/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRIX
• CIK: 1006045
• Web: www.iridex.com
• Phone: (650) 940-4700
• Fax: 650-940-4710
• Employees: 120
• Year Founded: 1989

Price Target and Rating

• Average Stock Price Target: $2.00
• High Stock Price Target: $2.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +73.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,570,000.00
• Net Margins: -22.79%
• Pretax Margin: -22.51%
• Return on Equity: -192.95%
• Return on Assets: -33.97%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 1.54
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $48.67 million
• Price / Sales: 0.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 16,789,000
• Free Float: 15,422,000
• Market Cap: $19.39 million
• Optionable: Optionable
• Beta: 0.69